Asterias Biotherapeutics, Inc. 4
4 · Asterias Biotherapeutics, Inc. · Filed Jun 28, 2017
Insider Transaction Report
Form 4
Spink Katharine E.
Vice President & COO
Transactions
- Award
Stock Option
2017-06-26+50,000→ 50,000 totalExercise: $3.70Exp: 2027-06-26→ Common Stock (50,000 underlying)
Holdings
- 192,500
Stock Option
Exercise: $2.34Exp: 2020-03-09→ Common Stock (192,500 underlying) - 150,000
Stock Options
Exercise: $3.45Exp: 2027-03-30→ Common Stock (150,000 underlying) - 165,000
Stock Option
Exercise: $3.64Exp: 2026-02-26→ Common Stock (165,000 underlying) - 100,000
Stock Option
Exercise: $3.90Exp: 2025-02-12→ Common Stock (100,000 underlying) - 10,949
Common Stock
- 100,000
Stock Option
Exercise: $5.45Exp: 2025-11-04→ Common Stock (100,000 underlying)
Footnotes (6)
- [F1]Subject to Ms. Spink's continued employment with the Company, 25% of the stock options vest on the one year anniversary of the grant date and the remaining 75% of the options vests monthly over 36 months. The stock options are exercisable upon vesting.
- [F2]Of such stock options, 4,167 have vested not as of the date hereof. The stock options are exercisable upon vesting.
- [F3]Of such stock options, 41,668 have vested not as of the date hereof. The stock options are exercisable upon vesting.
- [F4]Of such stock options, 62,500 have vested not as of the date hereof. The stock options are exercisable upon vesting.
- [F5]Of such stock options, 110,000 have not vested as of the date hereof. The stock options are exercisable upon vesting.
- [F6]Of such stock options, 150,000 have not vested as of the date hereof. The stock options are exercisable upon vesting.